SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00

Eye Drop in Phase 2 Clinical Testing for Treatment of Wet-AMD

SAN FRANCISCO, CA -- (Marketwired) -- 07/31/13 -- Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its twelve month price target of from $10.50 to $14.00. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD). Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $5B of revenues in 2012. OHR's Wet-AMD clinical candidate Squalamine eye drops would seem to present a significant advantage relative to the aforementioned therapies considering the delivery method which is self-administered eye drops. Both Lucentis® and Eylea® require an injection into the back of the eye. The Squalamine Eye Drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD." Mr. Silver concludes, "OHR recently completed an up-listing to the Nasdaq, added two prestigious Board members including Dr. Thomas Riedhammer, the former President of Global Pharmaceuticals for Bausch & Lomb and strengthened its balance sheet, which according to the Company, gives them a cash runway into 2015."

To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit http://www.vistapglobal.com and click the "Download" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...

Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website www.vistapglobal.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Vista Partners LLC
877.215.4813
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.